Anchiano Therapeutics

OverviewSuggest Edit

Anchiano Therapeutics is a clinical-stage biotechnology company that develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer.
TypePublic
Founded2004
HQCambridge, MA, US
Websiteanchiano.com

Latest Updates

Employees (est.) (Jun 2019)19(+12%)
Share Price (May 2021)$16.6(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Anchiano Therapeutics

Stan Polovets

Stan Polovets

Chairman of the Board
Andrew Fine

Andrew Fine

Chief Financial Officer
Ron Knickerbocker

Ron Knickerbocker

Senior Vice President of Clinical Development and Data Sciences
Show more

Anchiano Therapeutics Office Locations

Anchiano Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
One Kendall Square Building 1400E Suite 14-105
Show all (1)

Anchiano Therapeutics Financials and Metrics

Anchiano Therapeutics Revenue

USD

Net income (FY, 2017)

9.8m

EBIT (FY, 2017)

(9.4m)

Market capitalization (17-May-2021)

34.9m

Closing stock price (17-May-2021)

16.6

Cash (31-Dec-2017)

1.5m
Anchiano Therapeutics's current market capitalization is $34.9 m.
USDFY, 2016FY, 2017

General and administrative expense

2.3m3.2m

R&D expense

2.4m6.2m

Operating expense total

4.6m9.4m

EBIT

(4.6m)(9.4m)
USDFY, 2016FY, 2017

Cash

4.6m1.5m

Accounts Receivable

868.0k400.0k

Current Assets

5.4m1.9m

PP&E

213.0k219.0k
USDFY, 2016FY, 2017

Net Income

(4.7m)(9.8m)

Depreciation and Amortization

41.0k51.0k

Accounts Payable

(491.0k)44.0k

Cash From Operating Activities

(3.7m)(8.5m)
Show all financial metrics

Anchiano Therapeutics Operating Metrics

FY, 2018

Phase I Trials Products

2

Phase II Trials Products

7

Phase III Trials Products

1
Show all operating metrics

Anchiano Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

100/100

SecurityScorecard logo

Anchiano Therapeutics Online and Social Media Presence

Embed Graph

Anchiano Therapeutics News and Updates

Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months

NEW YORK, March 22, 2021 /PRNewswire/ -- The Genesis Prize Foundation today announced that its co-founder Stan Polovets has stepped down as chairman of the board of Anchiano Therapeutics (NASDAQ ANCN), a biopharmaceutical company dedicated to the discovery, development, and...

Anchiano Therapeutics Reports Year-End 2019 Financial Results

CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for the year ended December 31, 2019.

Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for its third quarter and nine months ended September 30…

Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., President and Chief E…

Anchiano Therapeutics Reports Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today reported financial results for its second quarter and six months …

Anchiano Therapeutics Frequently Asked Questions

  • When was Anchiano Therapeutics founded?

    Anchiano Therapeutics was founded in 2004.

  • Who are Anchiano Therapeutics key executives?

    Anchiano Therapeutics's key executives are Stan Polovets, Andrew Fine and Ron Knickerbocker.

  • How many employees does Anchiano Therapeutics have?

    Anchiano Therapeutics has 19 employees.

  • Who are Anchiano Therapeutics competitors?

    Competitors of Anchiano Therapeutics include Centurion, Intra-Cellular Therapies and Oncoinvent.

  • Where is Anchiano Therapeutics headquarters?

    Anchiano Therapeutics headquarters is located at One Kendall Square Building 1400E Suite 14-105, Cambridge.

  • Where are Anchiano Therapeutics offices?

    Anchiano Therapeutics has an office in Cambridge.

  • How many offices does Anchiano Therapeutics have?

    Anchiano Therapeutics has 1 office.